The important advance in the diagnosis and therapy of non-small cell lung cancer (NSCLC) have been achieved over the past decades. Targeted therapy and immunotherapy bring significant survival benefits to the selected NSCLC patients, but the overall cure and survival rates for NSCLC are still unsatisfactory, particularly in advanced patients. Therefore, a lot of energy is devoted to the development of precise diagnoses to achieve early diagnosis. Meanwhile, the continuous research and development of new drugs and a large number of multi-center clinical trials have accelerated the entry of drugs into clinical applications. Precise diagnosis and combination therapies with high efficacy and low toxicity are required to extend the clinical benefit to a wider patient population and improve the prognosis of NSCLC.
The development of nanotechnology has brought new hope for the precise diagnosis and treatment of cancer. Functional biomaterials designed by nanotechnology can be used for targeted drug delivery, which can deliver drugs to tumor sites at fixed points, thereby reducing the toxic and side effects of drugs on normal tissues. At the same time, nanomaterials constructed by nanotechnology can significantly enhance the sensitivity and resolution of diagnosis, providing the possibility for early diagnosis and timely treatment of tumors. Therefore, we expect nanotechnology to bring precise diagnosis and treatment to patients with NSCLC, improving their overall survival rate and quality of life. The focus of this Research Topic is to explore the potential nanotechnology, nanomaterials, nano drug delivery system, nano-controlled release system, and nano-imaging in the diagnosis and(or) therapy of NSCLC. These may include, but are not limited to:
• Nano drug delivery system in the treatment of NSCLC
• Nano-controlled release system in the treatment of NSCLC
• Application of nanomaterials in the diagnosis of NSCLC, including but not limited to imaging diagnosis.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
The important advance in the diagnosis and therapy of non-small cell lung cancer (NSCLC) have been achieved over the past decades. Targeted therapy and immunotherapy bring significant survival benefits to the selected NSCLC patients, but the overall cure and survival rates for NSCLC are still unsatisfactory, particularly in advanced patients. Therefore, a lot of energy is devoted to the development of precise diagnoses to achieve early diagnosis. Meanwhile, the continuous research and development of new drugs and a large number of multi-center clinical trials have accelerated the entry of drugs into clinical applications. Precise diagnosis and combination therapies with high efficacy and low toxicity are required to extend the clinical benefit to a wider patient population and improve the prognosis of NSCLC.
The development of nanotechnology has brought new hope for the precise diagnosis and treatment of cancer. Functional biomaterials designed by nanotechnology can be used for targeted drug delivery, which can deliver drugs to tumor sites at fixed points, thereby reducing the toxic and side effects of drugs on normal tissues. At the same time, nanomaterials constructed by nanotechnology can significantly enhance the sensitivity and resolution of diagnosis, providing the possibility for early diagnosis and timely treatment of tumors. Therefore, we expect nanotechnology to bring precise diagnosis and treatment to patients with NSCLC, improving their overall survival rate and quality of life. The focus of this Research Topic is to explore the potential nanotechnology, nanomaterials, nano drug delivery system, nano-controlled release system, and nano-imaging in the diagnosis and(or) therapy of NSCLC. These may include, but are not limited to:
• Nano drug delivery system in the treatment of NSCLC
• Nano-controlled release system in the treatment of NSCLC
• Application of nanomaterials in the diagnosis of NSCLC, including but not limited to imaging diagnosis.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
